^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    H1299 cell lysate with iscomatrix adjuvant vaccine

    i
    Other names: H1299 cell lysate with iscomatrix adjuvant vaccine
    Associations

    News

    Trials
    Company:
    National Cancer Institute
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    over3years
    Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies. (PubMed, Transl Lung Cancer Res)
    Eight of 14 patients (57%) exhibited serologic responses to NY-ESO-1. Cyclophosphamide/celecoxib did not appear to increase immune responses or enhance vaccine-induced alterations in peripheral immune subsets. H1299 lysate vaccines with Iscomatrix™ induce immune responses to CTA and modulate peripheral immune subsets in a manner that may enhance antitumor immunity in patients with thoracic malignancies.
    Clinical • P1 data • P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTAG1B (Cancer/testis antigen 1B) • CD14 (CD14 Molecule)
    |
    PD-L1 expression • PD-1 expression
    |
    H1299 cell lysate with iscomatrix adjuvant vaccine • NY-ESO-1 Iscomatrix • celecoxib oral